Cambridge, MA
December 10, 2007

Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that preliminary results from the pivotal trial of romidepsin, the Company's novel histone deacetylase inhibitor, for cutaneous T-cell lymphoma (CTCL) were presented at the American Society of Hematology (ASH) Annual Meeting held in Atlanta, Georgia. Youn H. Kim, M.D. of the Stanford Comprehensive Cancer Center and an investigator in the study presented data on romidepsin in an oral session entitled "Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study". Full text of the abstract #123 can be viewed on the ASH website at www.hematology.org.

The results reported by Dr. Kim included 73 evaluable CTCL patients. An overall response rate of 37% (27/73) was reported, with four complete responses (6%), 23 partial responses (31%) and 40 patients with stable disease (55%). Six patients had progressive disease. Significant pruritus relief was observed in 37% of patients who had severe pruritus at baseline. Additionally, 38% of the patients who exhibited any pruritus at baseline reported significant relief from symptoms. Overall, the most common adverse events reported were nausea, fatigue, vomiting, aguesia, headache and anorexia. Minor ECG abnormalities that were asymptomatic, transient and did not generally affect drug administration or the ability to continue therapy were noted in 6% of patients.

" We are very pleased with the promising clinical results from our ongoing pivotal study in CTCL," commented William McCulloch, M.B., FRCP, Executive Vice-President and Chief Medical Officer at Gloucester Pharmaceuticals. "Romidepsin continues to demonstrate significant single-agent activity in the treatment of T-cell lymphomas as well as encouraging clinical response in combination with other cancer agents with a manageable toxicity profile."